Trial backs standard of care for rheumatic heart disease and atrial fibrillation - European Society of Cardiology

Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036
Email: press@escardio.org

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.

This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.

Funding: INVICTUS was an investigator-initiated trial funded by an arm's length grant from Bayer AG to the Population Health Research Institute.

Disclosures: None.

References and notes

¹INVICTUS will be discussed during:

²Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76:2982–3021.

³Zuhlke L, Karthikeyan G, Engel ME, et al. Clinical outcomes in 3343 children and adults with rheumatic heart disease From 14 low- and middle-income countries: Two-year follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY Study). Circulation. 2016;134:1456–1466.

⁴Karthikeyan G. Stroke risk in rheumatic heart disease. Heart. 2021;107:694–696.

⁵Karthikeyan G, Connolly SJ, Yusuf S. Overestimation of stroke risk in rheumatic mitral stenosis and the implications for oral anticoagulation. Circulation. 2020;142:1697–1699.

⁶Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373–498.

⁷Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018;392:161–174.

⁸Zuhlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36:1115–1122.

⁹Karthikeyan G, Connolly SJ, Ntsekhe M, et al. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020;225:69–77.

¹⁰CHA₂DS₂-VASc: Congestive heart failure, Hypertension, Age >75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65–74 years, Sex category (female).

About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world's largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.

Adblock test (Why?)